OverT Bio, a data-driven company working to enable the curative potential of cell therapies in solid tumors secures $16million in seed funding.
With participation from Fusion Fund, OMX Ventures, Alexandria Venture Investments, Gaingels, Civilization Ventures, Hawktail, and Cancer Research Institute, ARTIS Ventures and Wing VC led the round.
The money will be used by the business to develop discovery platforms that target the main obstacles to cell therapy in an effort to develop long-lasting and effective therapies for advanced solid tumours.
Its central platform looks up every gene in the genome to find the most advantageous genetic alterations that give immune cells new abilities. The business has also developed a high-throughput method to find novel, safe, and effective receptors and targets.
Read also – [Funding News] UT-based Zanskar Geothermal & Minerals Secures $30Million in Funding
To identify novel receptors and targets that are applicable to the entire human population, OverT leverages the immune response seen by cancer patients. The complete human genome is searched by the researchers in an effort to develop novel approaches for enhancing the durability and anti-tumor efficacy of cell treatments.
Dr. Mat Legut, co-founder and CEO of OverT said, “Cell therapies have shown, at least in blood cancers, that we can aim to completely cure patients that have even the most advanced diseases rather than just prolong their survival, With OverT’s ability to rapidly screen and engineer thousands of genes, we are building next-generation therapies to cure advanced cancers of the solid tissues.”
About OverT Bio
Drs. Mat Legut and Neville Sanjana founded OverT Bio in 2022 with the goal of addressing significant unmet medical needs in solid tumours. The company has created platforms for synthetic biology, single-cell multiomic analysis, and parallel genomic screening that integrate big data analysis techniques with cell engineering technologies.
